retatrutide creator Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation found. Adam Retatrutide (“reta”) is an experimental
Description
When classified by system organ classes, there was increased reporting of neoplasms (benign/malignant), including increased reporting of MTC and PTCs
A legitimate prescription is required for any new medication, particularly for those not yet approved beyond trials
Clinical trials did not identify insomnia as a statistically significant side effect

Trial participants who continued Retatrutide through 48 weeks maintained 91% of their weight loss without significant regain

The opposite approach produces better results
Hepatic Fat and MASH Research: Glucagon receptor activation promotes lipolysis and fatty acid oxidation in the liver, reducing hepatic fat content